Q-omics provides the consensus-scored MIR627 profile across patient tissues and cancer cell-line models. MIR627 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR627 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, MIR627 RNA expression shows 6,146 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, KIRP, and STAD as cancer lineages where MIR627 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR627 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR627 survival associations across molecular data types. MIR627 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR627 RNA expression–survival associations across cancer types. High MIR627 expression shows unfavorable associations in THCA, KIRP, READ, LUSC, DLBC and MESO. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify THCA as the clearest survival context for MIR627 RNA expression.
This table summarizes MIR627 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MIR627. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR627 shows lower tumor expression in KIRP and higher tumor expression in THCA. The KIRP box plot shows higher MIR627 RNA expression in normal versus tumor tissue (log2 FC = −0.205, t-test p = .021).
This table shows molecular features associated with MIR627 in patient tissues and cancer cell lines. In patient samples, MIR627 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
